US 11,739,297 B2
Method of increasing tumor killing activity of macrophages or monocytes comprising chimeric antigen receptor
Michael Klichinsky, Philadelphia, PA (US); Nicholas G. Minutolo, Philadelphia, PA (US); and Nicholas R. Anderson, Philadelphia, PA (US)
Assigned to Carisma Therapeutics Inc., Philadelphia, PA (US)
Filed by Carisma Therapeutics Inc., Philadelphia, PA (US)
Filed on Sep. 16, 2021, as Appl. No. 17/477,494.
Application 17/477,494 is a continuation of application No. PCT/US2021/035991, filed on Jun. 4, 2021.
Claims priority of provisional application 63/082,584, filed on Sep. 24, 2020.
Claims priority of provisional application 63/044,934, filed on Jun. 26, 2020.
Claims priority of provisional application 63/034,873, filed on Jun. 4, 2020.
Prior Publication US 2022/0000918 A1, Jan. 6, 2022
Int. Cl. C12N 5/0786 (2010.01); C07K 16/28 (2006.01); C07K 14/725 (2006.01); A61K 35/15 (2015.01); A61K 39/00 (2006.01); C07K 16/32 (2006.01); A61P 35/00 (2006.01); C12N 15/86 (2006.01); C07K 14/735 (2006.01); C07K 14/47 (2006.01); C07K 14/705 (2006.01); A61K 38/00 (2006.01)
CPC C12N 5/0645 (2013.01) [A61K 35/15 (2013.01); A61P 35/00 (2018.01); C07K 14/4703 (2013.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 14/70535 (2013.01); C07K 14/70596 (2013.01); C07K 16/2896 (2013.01); C07K 16/32 (2013.01); C12N 15/86 (2013.01); A61K 38/00 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/5158 (2013.01); C07K 2317/53 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01); C12N 2501/24 (2013.01); C12N 2501/52 (2013.01); C12N 2510/00 (2013.01); C12N 2740/15043 (2013.01)] 10 Claims
 
1. A method of modifying ex vivo a macrophage or monocyte comprising a chimeric antigen receptor (CAR) comprising:
(a) an extracellular domain,
(b) a transmembrane domain, and
(c) an intracellular domain, and
wherein the method comprises treating the macrophage or monocyte with a CD40 agonist,
thereby producing a modified macrophage or monocyte which exhibits increased tumor killing ability relative to an unmodified macrophage or monocyte.